NasdaqHealth CareBiological Products, (No Diagnostic Substances)ARLINGTON, MA

Eloxx Pharmaceuticals, Inc. ELOX

Ask your AI

Estimated market cap $53.08M4.04M shares, shares as of Aug 7, 2026CIK 1035354

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

47.1% of shares · 3 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in Eloxx Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 11, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Eloxx Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

1.90M shares

14 funds report ELOX. Values checked against market prices.

Funds own 72% of shares (Q2 2026)

22 funds hold the stock.

Q3 2026: 47% · 5,560 of ~8,900 funds reported so far

Q2 202672%
Q3 2026 (so far)47%

Q3 2026. 1 new, 3 added to, 2 trimmed, 9 exited since Q2 2026.

Top 13F holders
#
1	Aberdeen Group plc 13F ↗	400,000	$6.1M	unchanged
2	Nantahala Capital Management, LLC 13F ↗	400,000	$6.1M	-50.0%
3	Siren, LLC 13F ↗	400,000	$6.1M	unchanged
4	Stonepine Capital Management, LLC 13F ↗	381,977	$5.8M	-3.8%
5	Morgan Stanley 13F ↗	202,630	$3.1M	+13023.7%
6	Vanguard Capital Management LLC 13F ↗	78,680	$1.2M	unchanged
7	Geode Capital Management, LLC 13F ↗	19,946	$305.4K	New
8	Vanguard Fiduciary Trust Co 13F ↗	13,669	$209.3K	+28.9%
9	UBS Group AG 13F ↗	2,026	$31.0K	+218.1%
10	Vanguard Global Advisers, LLC 13F ↗	718	$11.0K	unchanged

Download CSV Every fund that holds ELOX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Eloxx Pharmaceuticals, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Eloxx Pharmaceuticals, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2026	22	—	2.90M	$40.2M
Q3 2026	14	-8	1.90M	$29.1M

Each point is a quarter-end, from Q2 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (29014R301). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes13 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history3 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Eloxx Pharmaceuticals, Inc.
Address: P.O. BOX 274, ARLINGTON, MA 02476
Phone: 781-577-5300
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: ELOX (Nasdaq)
Former names: Sevion Therapeutics, Inc. (until 2017); SENESCO TECHNOLOGIES INC (until 2014); NAVA LEISURE USA INC (until 1999)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$13.15+$0.26 (+2.02%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $12.21 · High $13.70Nov 13, 2026

Aug 13, 2026Low $12.21 · High $20.98Nov 13, 2026

Jun 9, 2026Low $10.95 · High $20.98Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.